Skip to main content

xanomeline and trospium chloride 30 mg/1 / 125 mg/1 Medicare Part D Coverage

Brand name: Cobenfy
Dosage form
CAPSULE, COATED PELLETS
Route
ORAL
100%
of Medicare Part D plans
cover xanomeline and trospium chloride
5,529 of 5,530 plans
4.7
Avg. formulary tier

Formulary Tier Distribution

How Medicare Part D plans classify xanomeline and trospium chloride. Lower tiers = lower copays.

Tier 1 - Preferred Generic 3%
163 plans • avg $0.00/mo
Tier 2 - Generic 0%
2 plans • avg $0.00/mo
Tier 3 - Preferred Brand 1%
56 plans • avg $47.00/mo
Tier 4 - Non-Preferred Drug 21%
1,166 plans • avg $1.50/mo
Tier 5 - Specialty 75%
4,122 plans • avg $0.00/mo
Tier 6 - Select Care 0%
20 plans • avg $0.00/mo

Find the cheapest plan for xanomeline and trospium chloride

Enter your ZIP code to compare every plan in your area side-by-side.

Compare Plans for xanomeline and trospium chloride →

Get xanomeline and trospium chloride Delivered to Your Door

Compare prices and get discounts from trusted online pharmacies

DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.

xanomeline and trospium chloride Medicare Coverage by State

Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.

Frequently Asked Questions about xanomeline and trospium chloride

100% of Medicare Part D plans cover xanomeline and trospium chloride. It is most commonly placed on Tier 5. Coverage varies by plan and geographic area.

Costs vary by plan. Enter your ZIP code above to see exact prices for plans in your area.

xanomeline and trospium chloride is placed on Tier 5 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.

0% of plans require prior authorization for xanomeline and trospium chloride. Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.

Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →